Literature DB >> 4033409

Skeletal complications of Gaucher disease.

D W Stowens, S L Teitelbaum, A J Kahn, J A Barranger.   

Abstract

Gaucher disease is a collection of related disorders of sphingolipid catabolism caused by the deficiency of a specific beta-glucosidase. The inefficiency of this enzyme, glucocerebrosidase, to degrade its natural substrate leads to the accumulation of the complex lipid glucocerebroside in tissue macrophages. The pathogenesis of the disease is, as yet, poorly understood. The manifestations of the disease are protean with hepatosplenomegaly and bone deterioration frequently the predominating signs. The disease most frequently causes disability because of its effects on the skeleton. This review seeks to summarize the current clinical understanding of these complications. Experience with 327 patients reveals that the bone disease in this disorder is extremely variable. The severity of the problems range from asymptomatic persons with neither radiographic, scintigraphic, nor histologic evidence of bone involvement to those whose skeleton is completely devastated by a process of osteopenia, osteonecrosis, and osteosclerosis. These severely affected individuals show the most bizarre deformities in their bones and are subject to pathologic fracture. Most patients fortunately, are less profoundly affected, but many are plagued by bone pain of an arthritic nature or by an acute prostrating bone crisis probably best described as a bone infarction. The accepted etiology that these crises are a result of vascular compromise produced by occlusion of vessels by Gaucher cells is not supported by scintigraphic or histologic studies. Moreover, the vascular hypothesis does not explain the variety of lesions of the skeleton seen in this multifocal bone disease. Preliminary metabolic and endocrinologic studies suggest that this is not a systemic disorder of metabolism which affects bone uniformly. On the contrary, the lesions are multiple and localized, and sometimes much of the skeleton is preserved. These observations suggest that bone is affected because of collections of Gaucher cells scattered throughout its substance and may be the result of a toxic process around these foci. Alternatively, the storage of glucocerebroside in tissue macrophages may disturb the generation of competent osteoclasts and thus result in a failure to maintain a healthy skeleton. Further research is needed to delineate the pathogenesis of this disorder before any effective therapy can be developed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4033409     DOI: 10.1097/00005792-198509000-00003

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  28 in total

1.  Gaucher disease with pathological femoral neck fracture.

Authors:  Emine Binnetoglu; Erkam Komurcu; Hacer Sen; Betul Kizildag
Journal:  BMJ Case Rep       Date:  2013-08-30

2.  Gaucher disease and bone: laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy.

Authors:  G Ciana; R Addobbati; G Tamaro; A Leopaldi; M Nevyjel; L Ronfani; L Vidoni; M G Pittis; B Bembi
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

3.  Hemorrhage associated with "bone crisis" in Gaucher's disease identified by magnetic resonance imaging.

Authors:  G Horev; L Kornreich; H Hadar; K Katz
Journal:  Skeletal Radiol       Date:  1991       Impact factor: 2.199

4.  Radiographic findings in type 3b Gaucher disease.

Authors:  S C Hill; B M Damaska; M Tsokos; C Kreps; R O Brady; N W Barton
Journal:  Pediatr Radiol       Date:  1996-12

5.  Long-term bone mineral density response to enzyme replacement therapy in a retrospective pediatric cohort of Gaucher patients.

Authors:  Giovanni Ciana; Laura Deroma; Anna Martina Franzil; Andrea Dardis; Bruno Bembi
Journal:  J Inherit Metab Dis       Date:  2012-03-23       Impact factor: 4.982

6.  Gaucher disease--the orthopaedic aspect. Report of seven cases.

Authors:  C Tauber; T Tauber
Journal:  Arch Orthop Trauma Surg       Date:  1995       Impact factor: 3.067

7.  Correlation of MRI-Based bone marrow burden score with genotype and spleen status in Gaucher's disease.

Authors:  Robert F DeMayo; Andrew H Haims; Matthew C McRae; Ruhua Yang; Pramod K Mistry
Journal:  AJR Am J Roentgenol       Date:  2008-07       Impact factor: 3.959

8.  Retarded bone formation in GM1-gangliosidosis: a study of the infantile form and comparison with two canine models.

Authors:  J Alroy; K Knowles; S H Schelling; E M Kaye; A E Rosenberg
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

Review 9.  Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements.

Authors:  Gregory A Grabowski; Generoso Andria; Antonio Baldellou; Pauline E Campbell; Joel Charrow; Ian J Cohen; Chris M Harris; Paige Kaplan; Eugen Mengel; Miguel Pocovi; Ashok Vellodi
Journal:  Eur J Pediatr       Date:  2003-12-16       Impact factor: 3.183

10.  Review of the safety and efficacy of imiglucerase treatment of Gaucher disease.

Authors:  Deborah Elstein; Ari Zimran
Journal:  Biologics       Date:  2009-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.